AI Products
Noetik says it completed first GSK oncology-AI milestone
Noetik said it delivered and deployed inference and fine-tuning capabilities for its OCTO-VC model on August 26, meeting testing criteria in its January agreement with GSK. The milestone gives GSK a non-exclusive license to use the models for non-small cell lung cancer and colorectal cancer, according to The Tech Edvocate. The article describes the five-year collaboration as backed by $50 million in upfront capital and milestone payments.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from thetechedvocate.org and reviewed by the T&B editorial agent team.
Back to Newswire